10/644,687

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1201txs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS 2 | | "Ask CAS" for self-help around the clock |
| NEWS 3 | Jul 12 | BEILSTEIN enhanced with new display and select options, resulting in a closer connection to BABS |
| NEWS 4 | Jul 30 | BEILSTEIN on STN workshop to be held August 24 in conjunction with the 228th ACS National Meeting |
| NEWS 5 | AUG 02 | IFIPAT/IFIUDB/IFICDB reloaded with new search and display fields |
| NEWS 6 | AUG 02 | CAplus and CA patent records enhanced with European and Japan Patent Office Classifications |
| NEWS 7 | AUG 02 | The Analysis Edition of STN Express with Discover! (Version 7.01 for Windows) now available |
| NEWS 8 | AUG 04 | Pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! will change September 1, 2004 |
| NEWS 9 | AUG 27 | BIOCOMMERCE: Changes and enhancements to content coverage |
| NEWS 10 | AUG 27 | BIOTECHABS/BIOTECHDS: Two new display fields added for legal status data from INPADOC |
| NEWS 11 | SEP 01 | INPADOC: New family current-awareness alert (SDI) available |
| NEWS 12 | SEP 01 | New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover! |
| NEWS 13 | SEP 01 | New display format, HITSTR, available in WPIDS/WPINDEX/WPIX |
| NEWS 14 | SEP 14 | STN Patent Forum to be held October 13, 2004, in Iselin, NJ |
| NEWS 15 | SEP 27 | STANDARDS will no longer be available on STN |
| NEWS 16 | SEP 27 | SWETSCAN will no longer be available on STN |

| | |
|---|---|
| NEWS EXPRESS | JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:23:22 ON 28 SEP 2004

=> file reg
COST IN U.S. DOLLARS

| | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 28 SEP 2004


Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1
DICTIONARY FILE UPDATES: 27 SEP 2004 HIGHEST RN 752974-11-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\STNEXP4\QUERIES\106646872.str




chain nodes :
15 16 17 18 19 20 21 22 23 24 25 26 27 28
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
4-27 10-15 10-16 11-26 13-17 17-18 17-24 17-25 18-19 19-20 20-21 21-22 22-23 27-28
ring bonds :
1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14

exact/norm bonds :
1-10 6-7 11-26
exact bonds :
1-2 1-6 2-3 3-4 4-5 4-27 5-6 8-9 9-10 10-15 10-16 13-17 17-18 17-24
17-25 18-19 19-20 20-21 21-22 22-23 27-28
normalized bonds :
7-8 7-11 8-14 11-12 12-13 13-14
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS 28:CLASS

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 17:24:08 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11 TO 389
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2004 ACS on STN
IN 6H-Dibenzo[b,d]pyran-9-methanol, 3-[1,1-di(methyl-d2)heptyl-2-d]-
6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)-rel- (9CI)
MF C25 H33 D5 O3

Relative stereochemistry.



ALL ANSWERS HAVE BEEN SCANNED

```
=> s l1 ful
FULL SEARCH INITIATED 17:24:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    193 TO ITERATE

100.0% PROCESSED     193 ITERATIONS                              8 ANSWERS
SEARCH TIME: 00.00.01

L3             8 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             155.84     156.05

FILE 'CAPLUS' ENTERED AT 17:24:34 ON 28 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 Sep 2004  VOL 141 ISS 14
FILE LAST UPDATED: 27 Sep 2004  (20040927/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l3
L4          266 L3

=> s l4 and dexanabinol
            61 DEXANABINOL
L5          48 L4 AND DEXANABINOL

=> s l5 and enantiomer
         21135 ENANTIOMER
         23433 ENANTIOMERS
         33946 ENANTIOMER
                 (ENANTIOMER OR ENANTIOMERS)
L6           5 L5 AND ENANTIOMER

=> s l5 and enantiomer?
         50939 ENANTIOMER?
L7           6 L5 AND ENANTIOMER?

=> s l4 and cannabinoid
          4991 CANNABINOID
```

```
          4030 CANNABINOIDS
          5833 CANNABINOID
                 (CANNABINOID OR CANNABINOIDS)
L8         231 L4 AND CANNABINOID

=> d l7 ibib hitstr abs 1-6

L7   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2004:473361  CAPLUS
DOCUMENT NUMBER:          141:28689
TITLE:                    High enantiomeric purity dexanabinol
                          for pharmaceutical compositions
INVENTOR(S):              Aviv, Haim; Bar, Raphael; Schickler, Michael; Amselem,
                          Shimon
PATENT ASSIGNEE(S):       Israel
SOURCE:                   U.S. Pat. Appl. Publ., 28 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2004110827         A1    20040610    US 2003-644687           20030819
     WO 2004050011         A2    20040617    WO 2003-IL1023           20031203
     WO 2004050011         A3    20040729
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM,
             AZ, BY, KG, KZ
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.:                       IL 2002-153277      A  20021204
                                             US 2003-644687      A  20030819
IT   112924-45-5P, Dexanabinol
     RL: PUR (Purification or recovery); THU (Therapeutic use); BIOL
     (Biological study); PREP (Preparation); USES (Uses)
        (high enantiomeric purity dexanabinol for
        pharmaceutical compns.)
RN   112924-45-5  CAPLUS
CN   6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-
     tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI)  (CA INDEX NAME)

Absolute stereochemistry.
```



IT **112830-95-2**
RL: REM (Removal or disposal); PROC (Process)
(high **enantiomeric** purity **dexanabinol** for pharmaceutical compns.)
RN 112830-95-2 CAPLUS
CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aR,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



AB The present invention relates to a synthetic cannabinoid, **dexanabinol**, of **enantiomeric** purity in excess of 99.90%, or to a pharmaceutically acceptable salt, ester or solvate of said compound The present invention also relates to pharmaceutical grade compns. comprising said compound of high **enantiomeric** purity, and uses thereof for prevention and treatment of neurol. disorders, chronic degenerative diseases, CNS poisoning, cognitive impairment, inflammatory diseases or disorders, autoimmune diseases or disorders, pain, emesis, glaucoma and wasting syndromes.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:392439 CAPLUS
DOCUMENT NUMBER: 140:400095
TITLE: Stereoisomers of p-hydroxy-milnacipran, and therapeutic use
INVENTOR(S): Rariy, Roman V.; Heffernan, Michael; Buchwald, Stephen L.; Swager, Timothy M.
PATENT ASSIGNEE(S): Collegium Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004039320 | A2 | 20040513 | WO 2003-US33681 | 20031022 |
| WO 2004039320 | A3 | 20040624 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 2004142904 | A1 | 20040722 | US 2003-691465 | 20031022 |
| PRIORITY APPLN. INFO.: | | | US 2002-421640P P | 20021025 |
| | | | US 2002-423062P P | 20021101 |
| | | | US 2003-445142P P | 20030205 |

OTHER SOURCE(S): MARPAT 140:400095
IT **112924-45-5, Dexanabinol**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(p-hydroxymilnacipran stereoisomers, therapeutic use, and use with other agents)
RN 112924-45-5 CAPLUS
CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB The invention relates generally to the **enantiomers** of p-hydroxymilnacipran or congeners thereof. Biol. assays revealed that racemic p-hydroxymilnacipran is approx. equipotent in inhibiting serotonin and norepinephrine uptake (IC50 = 28.6 nM for norepinephrine, IC50 = 21.7 nM for serotonin). Interestingly, (+)-p-hydroxymilnacipran is a more potent inhibitor of norepinephrine uptake than serotonin uptake (IC50 = 10.3 nM for norepinephrine, IC50 = 22 nM for serotonin). In contrast, (-)-p-hydroxymilnacipran is a more potent inhibitor of serotonin uptake compared to norepinephrine uptake (IC50 = 88.5 nM for norepinephrine, IC50 = 40.3 nM for serotonin). The invention also relates to salts and prodrug forms of the above compds. In certain embodiments, the compds. of the

invention and a pharmaceutically acceptable excipient are combined to prepare a formulation for administration to a patient. Finally,the invention relates to methods of treating mammals suffering from various afflictions, e.g., depression, chronic pain, or fibromyalgia, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of the invention. Compound preparation is included.

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:13489 CAPLUS
DOCUMENT NUMBER: 135:70407
TITLE: **Dexanabinol** Pharmos
AUTHOR(S): Pop, Emil
CORPORATE SOURCE: Alchem Laboratories Corporation, Alachua, FL, 32615, USA
SOURCE: Current Opinion in Investigational Drugs (PharmaPress Ltd.) (2000), 1(4), 494-503
CODEN: COIDAZ
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT **112924-45-5P, Dexanabinol**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(therapeutic uses of **dexanabinol**)
RN 112924-45-5 CAPLUS
CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic uses of **dexanabinol**
AB A review, with 106 refs. **Dexanabinol** is a non-psychotropic cannabinoid NMDA receptor antagonist under development by Pharmos Corp for the potential treatment of cerebral ischemia, glaucoma, Alzheimer's disease, cardiac failure, head injury and multiple sclerosis (MS); it is in phase III trials for traumatic brain injury (TBI). **Dexanabinol** was licensed to Pharmos for development from its originator, the Hebrew University of Jerusalem. Pharmos is seeking to enter into a strategic agreement with another company to develop and commercialize **dexanabinol.** Unlike its **enantiomer**, HU-210 (Yissum Research Development Co), **dexanabinol** does not interact with

cannabinoid receptors. It has also exhibited more effective antioxidant and anti-inflammatory properties than MK-801 (dizocilpine; Merck & Co Inc). In addition, **dexanabinol** is generally well tolerated and appears toxicol. safe. Pharmos has been awarded a Small Business Innovation Research grant from the National Institutes of Health (NIH) National Institute of Neurol. Disorders and Stroke, Division of Stroke and Trauma. The grant covers the development of new prodrugs and novel formulations of **dexanabinol** and will support addnl. study of **dexanabinol** compds. for various indications. The prodrugs being studied are part of the group of compds. that include **dexanabinol** . A Notice of Allowance was received in Mar. 1999 on a patent covering the use of the drug in the treatment of MS. The use of **dexanabinol** and its derivs. to treat MS is described in US-05932610. An oral formulation of **dexanabinol** is claimed in US-05891468. **Dexanabinol** analogs with special utility in acute and chronic pain are claimed in US-04876276, while **dexanabinol** analogs for neuroprotection are claimed in US-06096740. Pharmos ests. that the worldwide market for **dexanabinol** in the treatment of severe head trauma may reach $1 billion per yr.

REFERENCE COUNT: 106 THERE ARE 106 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:614231 CAPLUS
DOCUMENT NUMBER: 133:275752
TITLE: Nonpsychotropic synthetic cannabinoids
AUTHOR(S): Pop, Emil
CORPORATE SOURCE: Alchem Laboratories Corporation, Alachua, FL, USA
SOURCE: Current Pharmaceutical Design (2000), 6(13), 1347-1359
CODEN: CPDEFP; ISSN: 1381-6128
PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

IT **112924-45-5, Dexanabinol**
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonpsychotropic synthetic cannabinoids)

RN 112924-45-5 CAPLUS
CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB A review with 61 refs. Unlike natural cannabinoids which belong to the

6aR - trans series, the synthetic **dexanabinol** (HU-211), a 6aS-trans **enantiomer**, does not have affinity toward cannabinoid receptors and is devoid of cannabimimetic activity. On the other hand, **dexanabinol** demonstrated significant neuroprotective properties which prompted its development as a therapeutic agent. We now present the extension of a series of 6aS-trans cannabinoids with novel derivs., including water soluble derivs. and congeners of **dexanabinol.**

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:747199 CAPLUS
DOCUMENT NUMBER: 128:74980
TITLE: Dimerization of **dexanabinol** by hydrogen bonding accounts for its hydrophobic character
AUTHOR(S): Pop, Emil; Brewster, Marcus E.
CORPORATE SOURCE: Pharmos Corporation, Alachua, FL, 32615, USA
SOURCE: International Journal of Quantum Chemistry (1997), 65(6), 1057-1064
CODEN: IJQCB2; ISSN: 0020-7608
PUBLISHER: John Wiley & Sons, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **112924-45-5, Dexanabinol**
RL: PRP (Properties)
(monomer and hydrogen-bonded dimer; dimerization of **dexanabinol** by hydrogen bonding in relation to hydrophobicity)

RN 112924-45-5 CAPLUS
CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB **Dexanabinol** (I), a dihydroxylated synthetic cannabinoid, is a member of the nonpsychotropic (+)-3S,4S **enantiomeric** series. Exptl. evidence suggests that I might form aggregates (e.g., dimers) in which the 2 OH (a phenol and an allylic alc.) groups are involved in H bonding. The extremely low solubility of I in H2O implies that this interaction may not involve solvent mols. A theor. study of this phenomenon in the framework of the PM3 mol. approximation is described. Simple mol. models (PhOH and 1-cyclohexene-1-methanol) were initially examined, followed by extension of the calcns. to I. I dimers resulting from H bonding are more stable than the isolated mols., with the differences attributed to H-bonding energies. The phenolic hydroxy group of 1 mol. forms an H bond with the allylic OH group of the 2nd mol. and vice versa, resulting in dimers containing 2 H bonds. The H bonds are more stable (6.14

kcal/mol) and the complex formed is more favored energetically when the phenol groups act as H-bond donors and the allylic OH groups as acceptors. These interactions are also energetically more favored than those between I and H2O (3.70 kcal/mol). The I dimer showed a lower dipole moment than the monomer (1.211 vs. 2.221 D) as well as a much larger log P (11.16 vs. 5.90), indicating strong hydrophobic character. The optimized structure shows that the OH groups involved in H bonds are oriented toward the interior of the dimers, while the lipophilic side chains are oriented toward the exterior. These properties of the dimer may explain the low water solubility of I.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:326857 CAPLUS
DOCUMENT NUMBER: 126:308812
TITLE: Tumor necrosis factor alpha (TNF-α)-inhibiting pharmaceuticals containing Δ6-tetrahydrocannabinol-type compounds
INVENTOR(S): Shohami, Esther; Gallily, Ruth; Mechoulam, Raphael
PATENT ASSIGNEE(S): Yissum Research Development Co. of the Hebrew University, Israel; Shohami, Esther; Gallily, Ruth; Mechoulam, Raphael
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9711668 | A2 | 19970403 | WO 1996-IL108 | 19960910 |
| WO 9711668 | A3 | 19970515 | | |
| W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA | | | | |
| IL 115245 | A1 | 20021201 | IL 1995-115245 | 19950911 |
| CA 2231764 | AA | 19970403 | CA 1996-2231764 | 19960910 |
| AU 9669420 | A1 | 19970417 | AU 1996-69420 | 19960910 |
| AU 708886 | B2 | 19990812 | | |
| EP 876143 | A2 | 19981111 | EP 1996-930337 | 19960910 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| JP 2000500737 | T2 | 20000125 | JP 1997-513269 | 19960910 |
| US 5932610 | A | 19990803 | US 1997-952660 | 19971117 |
| US 6331560 | B1 | 20011218 | US 1999-318774 | 19990526 |
| US 2002049245 | A1 | 20020425 | US 2001-971821 | 20011004 |
| US 6545041 | B2 | 20030408 | | |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | IL 1995-115245 | A | 19950911 |
| | WO 1996-IL108 | W | 19960910 |
| | US 1997-952660 | A1 | 19971117 |
| | US 1999-318774 | A1 | 19990526 |

OTHER SOURCE(S): MARPAT 126:308812
IT **112924-45-5, Dexanabinol**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(tumor necrosis factor-α-inhibiting pharmaceuticals containing Δ6-tetrahydrocannabinol-type compds.)

RN 112924-45-5 CAPLUS

CN 6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS,10aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB Pharmaceutical compns. are described for preventing TNF toxicity, comprising as active ingredient the stereospecific (+) **enantiomer**, having the (3S,4S) configuration of Δ6-tetrahydrocannabinol type compds. The compns. are particularly effective in alleviating and even preventing neurotoxicity due to elevated levels of TNF, including septic shock, cachexia and trauma. They are also effective in the treatment of certain chronic degenerative diseases characterized by TNF production, including autoimmune diseases.

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 43.76 | 199.81 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -4.20 | -4.20 |

STN INTERNATIONAL LOGOFF AT 17:35:14 ON 28 SEP 2004